596PCombined inhibition of MEK and PI3KCA pathway induces synergic antitumor activity in HER2 amplified human colorectal cancer models.

MLA

Belli, V., et al. “596PCombined Inhibition of MEK and PI3KCA Pathway Induces Synergic Antitumor Activity in HER2 Amplified Human Colorectal Cancer Models.” Annals of Oncology, vol. 29, Oct. 2018, p. N.PAG. EBSCOhost, https://doi.org/10.1093/annonc/mdy281.141.

APA

Belli, V., Matrone, N., Napolitano, S., Martinelli, E., Castellone, M. D., Trusolino, L., Giunta, E. F., Falco, V. D., Zanaletti, N., & Vitiello, P. P. (2018). 596PCombined inhibition of MEK and PI3KCA pathway induces synergic antitumor activity in HER2 amplified human colorectal cancer models. Annals of Oncology, 29, N.PAG. https://doi.org/10.1093/annonc/mdy281.141

Chicago

Belli, V, N Matrone, S Napolitano, E Martinelli, M D Castellone, L Trusolino, E F Giunta, V De Falco, N Zanaletti, and P P Vitiello. 2018. “596PCombined Inhibition of MEK and PI3KCA Pathway Induces Synergic Antitumor Activity in HER2 Amplified Human Colorectal Cancer Models.” Annals of Oncology 29 (October): N.PAG. doi:10.1093/annonc/mdy281.141.